Gottlieb A, Gisondi P, Eells J, Peterson L, Kavanaugh A. Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. J of Skin [Internet]. 2020 Jan. 28 [cited 2024 Jul. 3];4(1):S2. Available from: https://jofskin.org/33014/index.php/skin/article/view/801